で公開中です! 詳しく見る
FULCのアイコン

Fulcrum Therapeutics

3.65 USD
-0.02
0.54%
終値時点 更新済み 10月16日 16:00 EDT
プレマーケット
時間外取引
3.65
0.00
0%
1日
-0.54%
5日間
-3.18%
1か月
-3.69%
3か月
4.29%
6か月
-54.32%
年初来
-66.58%
1年
-60.71%
5年間
-84.16%
10年間
-72.96%
 

概要: Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

従業員数: 55

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 4.5%
ニュートラル 93.2%
ネガティブ 2.3%
ニュートラル
Newsfile Corp
8 日前
Kaplan Fox is Investigating Claims Against Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors
New York, New York--(Newsfile Corp. - October 8, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
Kaplan Fox is Investigating Claims Against Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors
ニュートラル
Newsfile Corp
10 日前
Kaplan Fox Encourages Fulcrum Therapeutics, Inc. (FULC) Investors Who Suffered Losses to Learn About Their Legal Rights
New York, New York--(Newsfile Corp. - October 6, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
Kaplan Fox Encourages Fulcrum Therapeutics, Inc. (FULC) Investors Who Suffered Losses to Learn About Their Legal Rights
ニュートラル
Newsfile Corp
14 日前
Kaplan Fox Investor Alert: Fulcrum Therapeutics, Inc. (FULC) Investigated for Possible Securities Law Violations
New York, New York--(Newsfile Corp. - October 2, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
Kaplan Fox Investor Alert: Fulcrum Therapeutics, Inc. (FULC) Investigated for Possible Securities Law Violations
ニュートラル
Newsfile Corp
16 日前
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) and its Board for Possible Securities Law Violations
New York, New York--(Newsfile Corp. - September 30, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) and its Board for Possible Securities Law Violations
ニュートラル
Newsfile Corp
18 日前
Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (FULC) Investors of a Pending Securities Investigation
New York, New York--(Newsfile Corp. - September 28, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (FULC) Investors of a Pending Securities Investigation
ニュートラル
Newsfile Corp
22 日前
Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (FULC) Investors: The Firm is Investigating Possible Securities Law Violations
New York, New York--(Newsfile Corp. - September 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (FULC) Investors: The Firm is Investigating Possible Securities Law Violations
ニュートラル
GlobeNewsWire
23 日前
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)
BALA CYNWYD, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)
ニュートラル
Newsfile Corp
24 日前
Kaplan Fox Broadens its Investigation of Fulcrum Therapeutics, Inc. (FULC) for Possible Securities Law Violations
New York, New York--(Newsfile Corp. - September 22, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
Kaplan Fox Broadens its Investigation of Fulcrum Therapeutics, Inc. (FULC) for Possible Securities Law Violations
ニュートラル
Newsfile Corp
28 日前
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) to Learn More About the Firm's Investigation
New York, New York--(Newsfile Corp. - September 18, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) to Learn More About the Firm's Investigation
ニュートラル
Newsfile Corp
先月
Kaplan Fox Shareholder Alert: Fulcrum Therapeutics, Inc. (FULC) is Under Investigation for Possible Securities Law Violations
New York, New York--(Newsfile Corp. - September 16, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
Kaplan Fox Shareholder Alert: Fulcrum Therapeutics, Inc. (FULC) is Under Investigation for Possible Securities Law Violations
価格チャートは Lightweight Charts™ を使用して実装されています